In almost every case, health insurance does not cover shockwave therapy for musculoskeletal pain, soft tissue injuries, or erectile dysfunction. Major commercial insurers, Medicare, and most government programs classify extracorporeal shock wave therapy (ESWT) as experimental, investigational, or unproven, which means patients typically pay the full cost themselves. A few narrow exceptions exist for specific diagnoses under specific plans, and those are worth knowing before you assume a denial is final.
The Narrow Exceptions Worth Knowing
Most published medical policies land in the same place. UnitedHealthcare calls ESWT “unproven and not medically necessary for any musculoskeletal or soft tissue indications.”1UnitedHealthcare. Extracorporeal Shock Wave Therapy Anthem classifies it as “investigational and not medically necessary” and specifically names plantar fasciitis, shoulder tendinitis, tennis elbow, non-union fractures, Peyronie’s disease, and wound repair among the denied conditions.2Anthem. Extracorporeal Shock Wave Therapy Cigna takes the same position for any musculoskeletal condition.3Cigna. ESWT for Musculoskeletal Conditions Blue Cross NC, Blue Cross Blue Shield of Texas, Blue Shield of California, and Blue Cross Blue Shield of Massachusetts have all reached the same conclusion in their published policies.4Blue Cross NC. Extracorporeal Shock Wave Treatment for Musculoskeletal Conditions and Wound Healing
Within that near-uniform denial, four exceptions stand out.
Aetna and Calcific Shoulder Tendinopathy
Aetna is the only major commercial insurer that covers ESWT for a specific condition. Under Clinical Policy Bulletin 0649, Aetna considers shockwave therapy medically necessary for calcific tendinopathy of the shoulder when the patient has had symptoms for at least six months, has a calcium deposit of one centimeter or larger, and has failed conservative treatments such as rest, ice, and medication.5Aetna. Extracorporeal Shock-Wave Therapy For every other condition, including plantar fasciitis, tennis elbow, Achilles tendinopathy, erectile dysfunction, and wound healing, Aetna still calls ESWT experimental and investigational.6Aetna. Plantar Fasciitis Treatments
TRICARE and Chronic Plantar Fasciitis
TRICARE covers high-energy ESWT for chronic plantar fasciitis when the patient has had symptoms for at least six months and has failed six months of conservative therapy. The energy flux density must exceed 0.12 mJ/mm². Low-energy and radial ESWT for plantar fasciitis are not covered, and ESWT for any other indication, including lateral epicondylitis, is considered unproven.7TRICARE. Musculoskeletal System8TriWest Healthcare Alliance. High Energy Extracorporeal Shock Wave Therapy
VA Coverage for Two Conditions
The Veterans Affairs health system may cover high-energy ESWT for chronic plantar fasciitis (six months of symptoms plus six months of failed conservative treatment) and for chronic lateral epicondylitis (six months of elbow pain plus failure of at least two conventional therapies for four weeks or more). For shoulder tendinopathy, Achilles tendinopathy, bone fractures, and other conditions, the VA considers ESWT not medically necessary. Low-energy ESWT is classified as unproven even for plantar fasciitis.9U.S. Department of Veterans Affairs. Clinical Determination and Indication for Extracorporeal Shock Wave Therapy
Medicare: Effectively No Coverage
Medicare has no National Coverage Determination for ESWT. The relevant Local Coverage Determination (L38775, administered by Palmetto GBA) treats high-energy ESWT as “not reasonable and necessary” for musculoskeletal conditions, which blocks coverage for plantar fasciitis, shoulder tendinopathy, and epicondylitis.10Centers for Medicare & Medicaid Services. Extracorporeal Shock Wave Therapy Where no local determination applies, UnitedHealthcare Medicare Advantage plans fall back on UHC’s commercial policy, which also denies the service.11UnitedHealthcare. Orthopedic Procedures, Devices, and Products If you have Medicare Part B and your provider thinks the service won’t be covered, they can give you an Advance Beneficiary Notice (ABN) in advance, which puts the financial responsibility on you if you decide to go ahead. Without a signed ABN, a denial generally leaves the provider holding the cost.
Shockwave Therapy for Erectile Dysfunction
Coverage for ED is harder to find than coverage for any musculoskeletal use. Shockwave therapy is not FDA-approved for erectile dysfunction, which is the central barrier.12GoodRx. Shockwave Therapy for Erectile Dysfunction The American Urological Association classifies low-intensity ESWT for ED as investigational.2Anthem. Extracorporeal Shock Wave Therapy No major commercial insurer, Medicare plan, Medicaid program, or TRICARE covers it. Branded programs like Gainswave, CoreWave, and Rajavapulse fall into the same excluded category. The University of Utah describes the therapy as experimental and lists out-of-pocket costs of $400 to $500 per session across a typical six-session course.13University of Utah Health. Shockwave Therapy for Erectile Dysfunction
Insurance usually will cover the pieces around the therapy: the urology consultation, blood work, and penile Doppler ultrasound, along with established ED treatments.14New York Urology Specialists. Insurance Coverage for Shockwave Therapy for ED The shockwave sessions themselves do not qualify.
Why Insurers Deny It Even Though the FDA Has Approved Devices
The FDA has approved or cleared several ESWT devices over the past two decades for conditions including chronic heel pain, chronic plantar fasciitis, tennis elbow, and diabetic foot ulcers.15National Center for Biotechnology Information. Extracorporeal Shock Wave Therapy Mechanisms and Results16Federal Register. Classification of the Extracorporeal Shock Wave Device for Treatment of Chronic Wounds That approval does not translate into coverage. Cigna’s policy says plainly that “coverage decisions are not based solely on FDA approval.”3Cigna. ESWT for Musculoskeletal Conditions Blue Cross Blue Shield of Texas takes the same position.17Blue Cross Blue Shield of Texas. Extracorporeal Shock Wave Therapy Insurers run their own evidence reviews and apply a medical necessity standard that is often stricter than what the FDA uses to clear a device for market.
The reasons they cite are consistent across policies: conflicting trial results, small studies with weak blinding and subjective outcome measures, no standard protocol for the number of sessions or energy levels to use, an unclear mechanism of action, and short follow-up periods that cannot show whether any benefit lasts.18Univera Healthcare. Extracorporeal Shock Wave Therapy for Musculoskeletal Conditions and Soft Tissue Wounds
One narrow carve-out: Blue Shield of California’s policy acknowledges that some state or federal mandates, such as those applying to Federal Employee Program plans, may stop an insurer from denying FDA-approved technology on investigational grounds alone. In those cases, the insurer evaluates the service on medical necessity instead.19Blue Shield of California. Extracorporeal Shock Wave Treatment for Musculoskeletal Conditions If you have an FEP plan, that distinction is worth raising with your insurer.
What You Will Pay Without Coverage
Expect $100 to $500 per session, depending on the provider, geographic location, device type, and condition. Focused ESWT for deep tissue or chronic pain generally costs more than radial ESWT for more superficial problems. A musculoskeletal course typically runs three to six sessions. ED protocols usually involve six to twelve sessions spaced about a week apart.12GoodRx. Shockwave Therapy for Erectile Dysfunction A full course can therefore run $1,500 to $3,000 or more. Some clinics offer package pricing or financing.
How to Appeal a Denial
A denial is not the end of the process. Appeals move in two stages: an internal appeal to the insurer first, and then an external review by an independent third party if that fails.
The internal appeal should be in writing, and it is stronger when it includes peer-reviewed research supporting the treatment for your specific condition, documentation of your diagnosis with imaging and functional impairment measures, a record of the conservative treatments you have tried along with their duration and your response, and the correct CPT and ICD-10 codes for the proposed therapy. Your provider’s office can often help assemble this package.
If the internal appeal is denied, you can request an external review. Federal rules make external review available when a denial involves medical judgment or a determination that a treatment is experimental or investigational, which is precisely the basis insurers use to deny ESWT.20HealthCare.gov. External Review The written request must be filed within four months of the final internal denial. The external reviewer’s decision is binding on the insurer. The federal process is free; state-run processes may charge up to $25.
One billing note that affects appeals: shockwave therapy is mostly billed with Category III CPT codes (such as 0101T, 0102T, 0512T, 0513T, and 0864T for ED), which are temporary tracking codes for emerging procedures. The one Category I code is 28890, for high-energy ESWT for plantar fasciitis with anesthesia and ultrasound guidance. UnitedHealthcare’s policy warns that listing a code in a policy “does not imply any right to reimbursement or guarantee claim payment.”1UnitedHealthcare. Extracorporeal Shock Wave Therapy Radial ESWT and EPAT have no dedicated code and are sometimes billed under unlisted procedure codes like 20999 or 28899, which draw denials even more readily.
Kidney Stones Are a Different Story
If you landed here because a doctor mentioned shockwave treatment for kidney stones, gallstones, pancreatic stones, or salivary stones, the coverage picture above does not apply to you. Extracorporeal shock wave lithotripsy (ESWL) for stones is a well-established, widely covered procedure and sits outside the investigational classification that governs musculoskeletal and ED uses. The barriers described here are specific to ESWT for tendons, soft tissue, wounds, and sexual function.